Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -5.03% and closed at $1.70, with the total traded volume of 23,019.00 shares. During last trade its minimum price was $1.67 and it gained its highest price of $1.79 and has a total of 40.91 million outstanding shares.
On March 30, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, has been working closely with different advertising outlets to continue increasing demand for Earth Science Tech’s products across the country.
In April, Earth Science Tech will be featured in a half-page ad in Natural Awakenings magazine, a publishing outlet that reaches 4+ million consumers across the entire U.S., and several other countries. Additionally, the company’s advertising statistics show that 80% of their readers make purchases based on advertisements they see in Natural Awakenings. (http://www.naturalawakeningsmag.com)
“Natural Awakenings has historically had very high ROI opportunities for its advertisers,” said CSO and Director, Gabriel Aviles, “They reach a demographic that has disposable income, is passionate about health, and seeks natural alternatives. This is a great market for us to tell our story to.”
Also in April, the company will be working with MassRoots (MSRT) to build demand for our new product lines launching within Q2 2017. MassRoots is one of the largest web portals within the cannabis industry, and over 1,000,000 cannabis enthusiasts are registered with the platform. This is one of the best niche advertising locations for a cannabis-based product to reach. (https://massroots.com)
“MassRoots is hands down one of the best platforms to launch a cannabis-based (Indsutrial Hemp) product from,” said CMO Sergio Castillo, “We can reach nearly a million registered users, gain major brand recognition, and build early demand for our innovative new products. This is a great opportunity for maximum brand exposure.”
ENDEXX CORPORATION COM USD0.001 (OTCMKTS:EDXC) showing dropped/jumped of -2.99% and closed at $0.0519, after gaining total volume of 567,346.00 shares. It beta value stands at 0.91 points and has total market capitalization of $6.94 million and a total of 128.54 million outstanding shares.
ENDEXX CORPORATION COM USD0.001 (EDXC) on February 1, 2017 announced the launch of its new website Phytobites.com. This site offers quick and easy access to essential information to the Company’s new pet product line, Phyto-Bites, its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. See video link below.
In addition, the Company’s feature on the Fox News Channel’s highly rated Cory’s Corner has generated significant sales and has led to a surge in demand for its product. The new website will have the capability to handle the large influx of sales orders and better inform pet owner clients.
Todd Davis, CEO of Endexx, stated, “We had anticipated that our interview on Fox was going to garner a large amount of hits and we strategically timed the launch of our site to coincide with the air-time. As a result, the media coverage, which went viral, generated the highest volume 24 hour sales to date. This has also helped us with new potential commercial opportunities with major retailers and we look forward to updating our shareholders as discussions progress.”
Easton Pharmaceuticals Inc (OTCMKTS:EAPH) decreased -3.87% closed at $0.0298 and traded with total volume of 3.45 million shares, while the average trading remained 5.57 million shares. During last trade its minimum price was $0.03 and it gained the highest price of $0.03. Its market capitalization was $27.80 billion.
Easton Pharmaceuticals Inc (EAPH) on March 22, 2017 announced it has forwarded together with BMV Medica a $300,000 payment to CommonSense of Israel clearing the way for the closing of an anticipated exclusive sub-distribution agreement with a major, multi-national, pharmaceutical company for the women’s diagnostic product AL-Sense (AmnioSense). In addition, Easton / BMV through their commercial alliance partner Ackerman Pharma, provides update on the regulatory filing of Generic Cancer Drug Paclitaxell, currently licensed together with Docetaxel through Biolyse Pharma of St. Catherines Ontario, through “fast-track” third-party authorized reviewer DefiLatina Healthcare, S.A. de C.V. towards regulatory approval in Mexico and other parts of Latin America.
Easton Pharmaceuticals / BMV Medica, last week advanced a $300,000 payment to CommonSense of Israel as an additional payment to secure the rights to women’s diagnostic products AL-Sense and VS-Sense, with the majority of the payment advanced by Easton Pharmaceuticals. The payment was advanced after a detailed marketing plan was submitted to CommonSense by Easton / BMV and its soon to be sub-distribution partner, which competed with another large company who was attempting to also acquire the rights to AL-Sense. The payment by Easton / BMV was the last hurdle, prior to a sub-distribution agreement being executed with a multi-national pharmaceutical company for AL-Sense who have sales in the billions of dollars. Easton is now exchanging and reviewing documents and final agreements towards the execution of the sub-distribution agreement which would result in the launch of its second product (AmnioSense), starting in Mexico and Central America.